Administration of recombinant human GM-CSF (rhGM-CSF) can benefit patients undergoing bone marrow transplantation by promoting faster hematopoietic reconstitution and enhancing the ability of macrophages to combat infections and tumor cells (60). The gene discussed is CSF2; the disease is infection.